Title here

Text here

HANNAHS HOPE FOR GIANT AXONAL NEUROPATHY INC

AKA Hannah's Hope Fund

Rexford, NY

GuideStar Quick View Everything you need to know...

HANNAHS HOPE FOR GIANT AXONAL NEUROPATHY INC

Also Known As:
Hannah's Hope Fund
Physical Address:
Rexford, NY 12148 
EIN:
45-0593226
Web URL:
www.hannahshopefund.org
Leadership:
Mrs. Lori Sames
Detailed Financial and People Data included in the GuideStar Premium Report Report Added To Cart

Legitimacy Information

  • This organization is registered with the IRS.
  • This organization is required to file an IRS Form 990 or 990-EZ.

Institutional funders should note that an organization’s inclusion on GuideStar.org does not satisfy IRS Rev. Proc. 2011-33 for identifying supporting organizations.

Learn more about GuideStar Charity Check, the only pre-grant due diligence tool that is 100% compliant with IRS Rev. Proc 2011-33.


Forms 990 from IRS Additional Information IRS Form 990 is an annual document used by approximately one-third of all public charities to report information about their finances and operations to the federal government. GuideStar uses data from Form 990 to populate its database with financial information about nonprofit organizations. Posting Form 990 images on the GuideStar Web site is an ongoing process.

Forms 990 for 2011, 2010, 2009, 2008 are included in the GuideStar Premium Report. Upgrade Now Report Added To Cart

A multi-year analysis of key balance sheet, income statement, profitability and liquidity measures is available for this organization. Financial SCAN includes a detailed financial health analysis and peer comparison and benchmarking tool. Learn More

Financial SCAN

Financial SCAN

Key Financial SCAN Features

  • Financial Health Dashboard: Highlights key financial trends and ratios for a selected nonprofit organization over a period of up to five years.
  • Peer Comparison Dashboard: Compares the organization's financials with up to five peer nonprofits that you select.
  • Graphical Analysis: Provides multi-year graphs and an interpretive guide in a format ready to present to your clients.
  • Printable PDF Report: Provides a complete analysis of the organization for your records. The full report tells you what to look for and why it matters.
  • Advanced Search: Allows you to search by EIN (Employer Identification Number), organization name, city, state, revenue, expenses, and assets.

Annual Revenue & Expenses Additional Information Financial information on GuideStar is either digitized from Form 990 images we receive from the IRS or submitted by the nonprofits themselves through the GuideStar Exchange (990 filers cannot override Form 990 financial data). If your organization does not file a Form 990, 990-EZ, or 990-PF and you would like to have your financial data displayed in this section, join the GuideStar Exchange today!

Fiscal Year Starting: Jan 01, 2011
Fiscal Year Ending: Dec 31, 2011
Revenue
Total Revenue $540,783
Expenses
Total Expenses $485,219

Is this information up-to-date?
Claim your report and update your GuideStar Exchange profile today!

Financial data from Forms 990 for Year 2011, 2010, 2009, 2008 are included in the GuideStar Premium Report. Upgrade Now Report Added To Cart

A multi-year analysis of key balance sheet, income statement, profitability and liquidity measures is available for this organization. Financial SCAN includes a detailed financial health analysis and peer comparison and benchmarking tool. Learn More

Financial SCAN

Financial SCAN

Key Financial SCAN Features

  • Financial Health Dashboard: Highlights key financial trends and ratios for a selected nonprofit organization over a period of up to five years.
  • Peer Comparison Dashboard: Compares the organization's financials with up to five peer nonprofits that you select.
  • Graphical Analysis: Provides multi-year graphs and an interpretive guide in a format ready to present to your clients.
  • Printable PDF Report: Provides a complete analysis of the organization for your records. The full report tells you what to look for and why it matters.
  • Advanced Search: Allows you to search by EIN (Employer Identification Number), organization name, city, state, revenue, expenses, and assets.



GuideStar Exchange Member

This organization is a Silver-level GuideStar Exchange participant, demonstrating its commitment to transparency.

Is this your organization's report?
Update your organization's information today!


Basic Organization Information

HANNAHS HOPE FOR GIANT AXONAL NEUROPATHY INC

Also Known As:
Hannah's Hope Fund
Physical Address:
Rexford, NY 12148 
EIN:
45-0593226
Web URL:
www.hannahshopefund.org 
NTEE Category:
H Medical Research 
G Disease, Disorders, Medical Disciplines 
Ruling Year:
2008 

Sign in or create an account to see this organization's full address, contact information, and more!


Mission Statement

DEDICATED TO FUNDING RESEARCH FOR A TREATMENT AND/OR A CURE FOR GIANT AXONAL NEUROPATHY ABA: Hannah's Hope Fund for GAN,  Hannah's Hope Fund

A multi-year analysis of key balance sheet, income statement, profitability and liquidity measures is available for this organization. Financial SCAN includes a detailed financial health analysis and peer comparison and benchmarking tool. Learn More

Financial SCAN

Financial SCAN

Key Financial SCAN Features

  • Financial Health Dashboard: Highlights key financial trends and ratios for a selected nonprofit organization over a period of up to five years.
  • Peer Comparison Dashboard: Compares the organization's financials with up to five peer nonprofits that you select.
  • Graphical Analysis: Provides multi-year graphs and an interpretive guide in a format ready to present to your clients.
  • Printable PDF Report: Provides a complete analysis of the organization for your records. The full report tells you what to look for and why it matters.
  • Advanced Search: Allows you to search by EIN (Employer Identification Number), organization name, city, state, revenue, expenses, and assets.


Revenue and Expenses

Revenue and Expense data from Forms 990 for 2011, 2010, 2009, 2008 are included in the GuideStar Premium Report. Upgrade Now Report Added To Cart


Balance Sheet

Balance Sheet data from Forms 990 for Year 2011, 2010, 2009, 2008 are included in the GuideStar Premium Report. Upgrade Now Report Added To Cart

A multi-year analysis of key balance sheet, income statement, profitability and liquidity measures is available for this organization. Financial SCAN includes a detailed financial health analysis and peer comparison and benchmarking tool. Learn More

Financial SCAN

Financial SCAN

Key Financial SCAN Features

  • Financial Health Dashboard: Highlights key financial trends and ratios for a selected nonprofit organization over a period of up to five years.
  • Peer Comparison Dashboard: Compares the organization's financials with up to five peer nonprofits that you select.
  • Graphical Analysis: Provides multi-year graphs and an interpretive guide in a format ready to present to your clients.
  • Printable PDF Report: Provides a complete analysis of the organization for your records. The full report tells you what to look for and why it matters.
  • Advanced Search: Allows you to search by EIN (Employer Identification Number), organization name, city, state, revenue, expenses, and assets.


Forms 990 Provided by the Nonprofit


Financial Statements

Financial Statements for 2010 are included in the GuideStar Premium Report. Upgrade Now Report Added To Cart


Annual Reports

Sign in or create an account to view this information.






Officers for Fiscal Year (IRS Form 990)

Report Added To Cart Officers for 2011, 2010, 2009, 2008 are included in the GuideStar Premium Report. Upgrade Now


Highest Paid Employees & Their Compensation (IRS Form 990)

Highest Paid Employee data is not available for this organization.


Program: Natural History Study

Budget:
$300,000
Category:
Medical Research
Population Served:
Children and Youth (infants - 19 years.)
Adults

Program Description:

Giant Axonal Neuropathy Natural History Study Verified by: Columbia University, December 2011 First Received: December 29, 2011 | Last Updated: December 30, 2011 | Phase: N/A | Start Date: December 2011 Overall Status: Recruiting | Estimated Enrollment: 15 …Tell a FriendPrint Giant Axonal Neuropathy (GAN) is a devastating and rare childhood disease. Children with GAN develop increasing muscle weakness, impaired sensation, and at times mental retardation. GAN starts in infancy, leads to significant disability, and typically leads to death within the first 30 years of life. GAN is caused by a defect in the "gigaxonin" (GAN) gene, resulting in pathologically enlarged and... Brief Summary Official Title: “Clinical Study of Giant Axonal Neuropathy” Giant Axonal Neuropathy (GAN) is a devastating and rare childhood disease. Children with GAN develop increasing muscle weakness, impaired sensation, and at times mental retardation. GAN starts in infancy, leads to significant disability, and typically leads to death within the first 30 years of life. GAN is caused by a defect in the "gigaxonin" (GAN) gene, resulting in pathologically enlarged and dysfunctional nerves. Currently, there is no effective therapy. To find out what medications can help patients with GAN, the investigators have to conduct clinical trials. In this study, the investigators propose to prepare for future clinical trials and will invite GAN patients to join our research effort. The investigators will examine them regularly to better understand their disease. The visits will include questions, a physical exam, blood drawing, a lumbar puncture, and a skin biopsy. The visits will also include tests that assess the electrical conductivity of the patients' nerves as well as a test to measure the patients' brain wave activity. In addition, the investigators will be performing tests to evaluate the patients' motor function, their vision, and thinking ability. Identifying an effective GAN treatment is very important because there is currently none. Clinical trials are the only way to decide whether a new treatment works in GAN patients or not. With the future objective of conducting clinical trials in GAN, the proposed project has three specific aims. The first is to plan for clinical trials by developing reliable outcome measures, and establishing the infrastructure needed to carry out efficient clinical trials. The second is to further characterize the patient population from a clinical and molecular point of view, and the third aim is to utilize the information gathered in this study to further pre-clinical GAN drug development to select candidate drugs. Study Type: ObservationalStudy Design: Observational Model: Cohort, Time Perspective: ProspectiveStudy Primary Completion Date: December 2014Outcome Measures for this Clinical Trial Primary MeasuresGross Motor Function Measure (GMFM)Time Frame: Up to 24 months Safety Issue?: No Secondary MeasuresNerve Conduction Study (NCS)/Motor Unit Number Estimation (MUNE)Time Frame: Up to 24 months Safety Issue?: NoSomatosensory Evoked Potential (SSEP)Time Frame: Up to 24 months Safety Issue?: NoBrainstem Auditory Evoked Response (BAER)Time Frame: Up to 24 months Safety Issue?: NoPulmonary Function Testing (PFT)/Forced Vital Capacity (FVC)Time Frame: Up to 24 months Safety Issue?: No Criteria for Participation in this Clinical Trial Inclusion Criteria: 1. Clinical diagnosis of Giant Axonal Neuropathy.2. Documentation of the presence of a mutation in the GAN gene as determined by gene sequencing from a CAP/CLIA certified laboratory or an equivalent organization.3. Parents or if applicable subjects must give informed consent must be capable of complying with the study procedures.4. Willing and able to comply with all protocol requirements and procedures. Exclusion Criteria: 1. Unwilling or unable to travel to Columbia University Medical Center.2. Unstable medical condition precluding participation.3. Significant respiratory compromise that would interfere with safe travel to site of evaluation.4. Having a contraindication to the MRI safety requirements, including pacemaker or other implanted electrical device, brain stimulator, some types of dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), implanted delivery pump, shrapnel fragments, or history of claustrophobia. Gender Eligibility for this Clinical Trial: Both Minimum Age for this Clinical Trial: N/A Maximum Age for this Clinical Trial: N/A Are Healthy Volunteers Accepted for this Clinical Trial?: No Clinical Trial Investigator Information Lead Investigator: Columbia University Other Overall Clinical Trial Officials and Contacts Douglas M. Sproule, MD, MSc Principal Investigator Columbia University Overall Contact: Jonathan D. Marra, M.A. 212-305-2461 jdm2132@columbia.edu Additional Information Information obtained from ClinicalTrials.gov on March 15, 2012 Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT01503125 Study ID Number: AAAI4500 ClinicalTrials.gov Identifier: NCT01503125 Health Authority: United States: Institutional Review Board

Program Long-Term Success:

Program Short-Term Success:

Program Success Monitored by:

Program Success Examples:


Impact Summary from the Nonprofit

Hannah’s Hope Fund is a 501c3 public charity dedicated to finding a treatment and cure of Giant Axonal Neuropathy, (GAN), a rare, fatal disorder. Eight year old Hannah Sames, of Rexford, NY is the inspiration of Hannah’s Hope Fund, the only organization in the world focused on a treatment for this ravaging disorder. Children with GAN die of progressive nerve death. They eventually lose the ability to walk, move, speak and swallow. They die in the second of third decade, typically from pneumonia. Since August of 2008, the collaborative team of scientists working with Hannah’s Hope Fund have developed gene therapy to treat the nerve cells in the spinal cord and brain with a healthy copy of the GAN gene. Scientists use a benign viral vector as a delivery truck to transport a healthy copy of the GAN gene to nerve cells, providing a life sustaining protein that is missing in cells of children with GAN. The scientists working on this gene therapy approach for GAN feel it is ready for a human clinical trial. We met with the FDA on Jan. 26, 2012 and now have a clear path forward. If the FDA required safety studies go as planned, we will be ready to begin a trial this Fall of 2012. It is estimated that we need to raise another $500,000 to fund the Phase 1 clinical trial.  Since GAN is very rare, it doesn’t attract the attention of pharmaceutical or biotechnology companies due to smaller profits. Therefore, it is reality that the families of loved ones suffering from rare disorders must raise the funds for therapy development and clinical trials in order to saved loved ones. It is our hope that a Biotech will take over the project and bring it through Phase 2 and Phase 3 trials if the Phase 1 study reveals GAN gene therapy is safe, and the data indicate it either stops or slows progression of the disease. Please choose to get involved in our mission.

Organization Data Available

Adobe PDF Format A GuideStar Premium Report in PDF format is available for this organization

Price for this Report: $125.00

This Premium Report includes:

  • Financial Data for
  • Financial Charts for
  • Forms 990 for
  • Forms 990T for
  • Audited Financial Statement for
  • Annual Reports for
  • Letter of Determination
  • Form 1023 / 1024
  • Board Members
  • Officer, Director and/or Highest Paid Employee data for


Learn more about GuideStar Premium